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Objective: Runt-related transcription factor 2 (Runx2) and Osterix (Osx) are the master transcription
factors in bone formation. Nonetheless, genes acting downstream of both Runx2 and Osx have yet to be
fully characterized. Here, we investigate the downstream targets of both Runx2 and Osx in osteoblasts.
Materials and methods: DNA microarray analysis was conducted on calvarial RNA from wild-type, Runx2
heterozygous, Osx heterozygous, and Runx2/Osx double heterozygous embryos. Expression and tran-
scriptional responses of the selected target gene were analyzed in MC3T3-E1 osteoblastic cells.
Results: The expression of unique cartilage matrix-associated protein (Ucma) was decreased in
Runx2/Osx double heterozygous embryos. In contrast, Ucma expression was increased in osteoblasts
overexpressing both Runx2 and Osx. Ucma expression was initiated mid-way through osteoblast
differentiation and continued throughout the differentiation process. Transcriptional activity of the Ucma
promoter was increased upon transfection of the cells with both Runx2 and Osx. Runx2-and
Osx-mediated activation of the Ucma promoter was directly regulated by Runx2-and/or Sp1-binding
sites within its promoter. During osteoblast differentiation, the formation of mineralized nodules in
Ucma-overexpressing stable clones occurred earlier and was more enhanced than that in the mock-
transfected control. Mineralized nodule formation was strongly augmented in the cells cultured in a
medium containing secretory Ucma proteins.
Conclusion: Ucma is a novel downstream gene regulated by both Runx2 and Osx and it stimulates
osteoblast differentiation and nodule formation.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The bone morphogenetic protein (BMP) signaling pathway is
essential for the regulation of osteogenesis. BMP subtypes bind to
their receptors and activate Smads, which directly regulate target
gene expression1. In osteoblasts, BMP target genes include a
number of transcription factors, including distal-less homeobox 3o: J.-E. Kim, Department of
ty School of Medicine, 101
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syoon@chol.com (S.-Y. Park),
Y.C. Boo), jechoi@knu.ac.kr
ternational. Published by Elsevier L(Dlx3), Dlx5, activating transcription factor 4, Runt-related tran-
scription factor 2 (Runx2), and Osterix (Osx)2. Runx2 and Osx are
master transcriptional regulators of osteogenesis. Runx2 plays an
essential role in the differentiation of mesenchymal progenitor cells
into osteoblasts. A Runx2 deﬁciency inmice leads to a complete lack
of both endochondral and intramembranous bone formation due to
the arrest of osteoblast differentiation3,4. Osx is also important for
osteoblast differentiation and bone formation5. Despite normal
cartilage development, Osx-null mutants do not undergo bone
formation. Although Runx2 is expressed in Osx-null mutants, Osx is
not expressed in Runx2-null mice, indicating that Osx is down-
stream of Runx2 in osteoblast differentiation5. However, this is still
under debate. While Runx2 and Osx heterozygous mice display no
bone phenotypes, Runx2/Osx double heterozygous embryos
showed reduced bone length and absence of several bones6. Thesetd. All rights reserved.
Table II
List of primers for RT-PCR and qRT-PCR
Name Sequence
Osx S 50-CGTCCTCTCTGCTTGAGGAA-30
AS 50-CTTGAGAAGGGAGCTGGGTA-30
Runx2 S 50-CCGCACGACAACCGCACCAT-30
AS 50-CGCTCCGGCCCACAAATCTC-30
Ucma S 50-GATGCCTCCAATTTCCTCAA-30
AS 50-GGCATCAGAACAGAGGGTGT-30
Osteocalcin S 50-CCTCAGTCCCCAGCCCAGATCC-30
AS 50-CAGGGCAGAGAGAGAGGACAGG-30
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reduced mineralization of bone. BMP target genes, Runx2 and Osx,
regulate various other genes. Osteocalcin and bone sialoprotein,
which are markers of osteoblast differentiation, are directly
controlled by a complex Runx2-mediated mechanism7,8. During
bone formation, Osx regulates the transcription of genes encoding
the special AT-rich sequence-binding protein (Satb2) and the
vitamin D receptor through GC-rich-binding sites9,10. Osx also
controls the interleukin 1-a and collagen genes through an Sp1-
binding site in their promoters5,11,12. Underscoring the importance
of Runx2 and Osx, these results indicate that downstream genes
regulated by Runx2, Osx, or both may be required for osteoblast
differentiation.
To search for such genes that are important during osteo-
genesis, DNA microarray analysis was performed on calvarial RNA
isolated from wild-type, Runx2 heterozygous, Osx heterozygous,
and Runx2/Osx double heterozygous embryos. Among the 26
genes classiﬁed as regulators of osteogenesis and altered by Runx2
and/or Osx deﬁciency, unique cartilage matrix-associated protein
(Ucma) was markedly downregulated in double heterozygous
embryos compared to the embryos of other genotypes. Ucma is a
novel secreted factor present in fetal and juvenile growth plate
cartilage as well as in trabecular bone13e15. In developing long
bones, Ucma is expressed in resting chondrocytes13,14 and in os-
teoblasts and osteocytes of trabecular bone15. On the other hand,
its function and regulatory mechanisms remain unclear. In this
study, we explored the role of Ucma in osteoblast differentiation
and suggest that Ucma is a novel gene that is regulated by both
Runx2 and Osx during osteoblast differentiation and bone
formation.
Materials and methods
Animals and microarray materials
All animal experimental procedures were conducted with the
approval from the animal ethics committee of Kyungpook National
University. As described previously in Ref. 6, Osxþ/ mice were
crossed with Runx2DC/þ mice to generate four types of embryos:
Runx2þ/þ;Osxþ/þ (Wild-type, WT), Runx2DC/þ;Osxþ/þ (Runx2het),
Runx2þ/þ;Osxþ/ (Osxhet), and Runx2DC/þ;Osxþ/ double heterozy-
gous embryos (Doublehet) (Fig. S1). To collect calvariae from em-
bryos on embryonic day 18.5 (E18.5), we prepared three pregnant
females and the numbers of embryos collected from each female
are listed in Table I. Calvarial tissues of the same genotype were
pooled for each pregnant female. Total RNA was isolated from the
calvariae and cultured cells, using the TRIzol Reagent (Invitrogen,
Carlsbad, CA, USA). For microarray analysis of calvarial RNA, whole
pooled samples from the three sets were pooled again to attain
sufﬁcient concentrations of RNA. The cDNA synthesis was per-
formed using the SuperScript® III First-Strand Synthesis System
(Invitrogen). Gene expression proﬁles were analyzed using the
GeneChip® Mouse Gene 1.0 ST Array (Affymetrix, Santa Clara, CA,
USA).Table I
The samples and populations relevant to the study
No. of embryos from each genotype Analysis methods
WT Osxhet Runx2het Doublehet
1st female 4 1 4 2 RT-PCR, qRT-PCR
2nd female 1 1 5 2 RT-PCR, qRT-PCR
3rd female 1 2 3 2 RT-PCR, qRT-PCR
Total 6 4 12 6 MicroarrayRT-PCR and quantitative real-time PCR (qRT-PCR)
Total RNA extracted from the calvariae and cultured cells was
used to measure mRNA expression levels of the genes under study.
The sequences of the primers used in this study are listed in Table II.
Information regarding methods is provided in the Supplementary
data.
Cell culture and western blotting
The Supplementary data provide information regarding
methods.
Construction of the mouse Ucma promoter and reporter plasmids
To construct the mouse Ucma promoter, the transcription initi-
ation site of the mouse Ucma gene was determined using 50 rapid
ampliﬁcation of cDNA ends (50 RACE), in accordance with the
manufacturer's instructions (Invitrogen). The 50-ﬂanking region
(980 to þ51) of the mouse Ucma gene was ampliﬁed from the
genomic DNA of ATDC5 cells by using PCR and was cloned into the
NheIeXhoI sites of the pGL3/basic vector (Promega) to generate the
Ucma reporter plasmid pUcma-980. Three 50-deletion mutants of
the mouse Ucma promoter (459 to þ51, 222 to þ51, and 41
to þ51) were ampliﬁed using PCR and cloned into the
NheIeXhoI sites of the pGL3/basic vector. Mutations were intro-
duced into the Osx- and/or Runx2-binding sites within the mouse
Ucma promoter using the QuikChange site-directed mutagenesis
kit (Stratagene). The primer sequences are listed in Table III.
The reporter assay
MC3T3-E1 cells were seeded in 12-well culture plates at a
density of 8  104 cells/well. The next day, the cells were trans-
fected with either the pGL3/basic or the pUcma-luc vector, together
with either a Runx2 or an Osx expression vector by using Lip-
ofectamine (Invitrogen). At 48 h after transfection, luciferase ac-
tivity was measured using the Dual Luciferase assay system
(Promega). The transfection efﬁciency was determined in each
sample using co-transfection with a plasmid encoding RenillaOsteopontin S 50-GGCATTGCCTCCTCCCTC-30
AS 50-CGAGGCTGTAAAGCTTCTCC-30
Col2a1 S 50-CACACTGGTAAGTGGGGCAAGACCG-30
AS 50-GGATTGTGTTGTTTCAGGGTTCGG G-30
Sox9 S 50-CTCTGTTTTCCCTCCCTCCT-30
AS 50-TCCTCGCTCTCCTTCTTCAG-30
Aggrecan S 50-GAAGACGACATCACCATCCAG-30
AS 50-CTGTCTTTGTCACCCACACATG-30
GAPDH S 50-TGAAGGTCGGTGTGAACGGATTTGGC-30
AS 50-CATGTAGGCCATGAGGTCCACCAC-30
Table III
DNA sequences of oligonucleotides used in this study
Name Sequence
50 RACEePCR
Ucma (S) 50-GACTTCCAAGATACCTCACC-30
Ucma-1 (AS) 50-GTCCTCTCTTCCTGCTCATC-30
Ucma-2 (AS) 50-ACTTCATCTCGGGACTTAGG-30
Ucma-3 (AS) 50-TGTTTCACACTACACAGGAG-30
Cloning of Ucma promoter and its deletion constructs
pUcma-980 (S) 50-AAAAGCTAGCCTGGCTCCCTTTGAGGTG-30
pUcma-459 (S) 50-AAAAGCTAGCAGGAGATCCCATAGAAGTC-30
pUcma-222 (S) 50-AAAAGCTAGCACTCAGGCTGAGTATTTC-30
pUcma-41 (S) 50-AAAAAGCTAGCCTCTCCCCCAGTGGCATC-30
pUcmaþ51 (AS) 50-AAAACTCGAGCTGCCCAGTAAGTCCTCAC-30
Primers for site-directed mutagenesis
mGC 50-GACAGTTTAAAACTGCAAATGAAAGTTAAAACAAGC TCCACTTC-30
mSp1 50-ACCACAGCCAGGACAAATAAAACTCTCCCCCAGTGG-30
mRunx2 50-AGCAGCCAATGGAAAGTACAGCCAGGACCCCTCC-30
Primers for ChIP assay
p1 50-GGCCAAAAACATCTCCAGTG-30 and 50-CACAGAAGTGGAGCTTGTGG-30
p2 50-GCTTCTCCCACTTGGACTCA-30 and 50-CAGGCCAGAACACTGGAGAT-30
p3 50-TCCCTGGGAACAGTGTATCAG-30 and 50-CATATGGGGCCAGAGAAAGAA-30
Cloning of Ucma promoter and its deletion constructs. (The underlined nucleotides indicate NheI or XhoI site.) Primers for site-directed muta-
genesis. (The underlined nucleotides indicate mutated binding sites.)
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of Renilla luciferase.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed using the UPSTATE Kit (Millipore, Billerica,
MA, USA). The Supplementary data provide information regarding
the method. PCR was performed with the speciﬁc primers listed in
Table III.
Transient transfection and establishment of stable cell clones
To construct the mouse Ucma expression vector, Ucma cDNAwas
ampliﬁed from ATDC5 cells by PCR using the following primers: 50-T
TTTTGAATTCGACTTCCAAGATACCTCACC-30 and 50-TTTTTCTCGAG-
GATGTTTTGGCGGTTGTAG-30. The PCR product was digested with
EcoRIeXhoI and cloned into the same sites of the pcDNA3.1 vector
(Invitrogen) containing theFLAGepitope.A shRNAtarget sequence for
mouse Ucma (accession number: NM_026754), shUcma: 50-CG
AGTTTGAGAACTTCGTG-30, was selected using the OligoEngine siRNA
design tool. Forward and reverse oligonucleotides (sense-loop-anti-
sense) were synthesized, annealed, and cloned into the BglIIeHindIII
sites of the pSuper/puro vector (OligoEngine, Seattle, WA, USA). For
transient transfection,293FTcellswere seeded in6-well cultureplates
at a densityof 3 105 cells/well. Five hours after transfection, the cells
were serum-starved for 48 h, and the supernatants and cell lysates
were collected for analysis by western blotting. To achieve stable
transfection, MC3T3-E1 cells were transfected with either the Ucma
expression vector or the knockdown vector, and the transfectant
cloneswere selected inmedia containing 500 mg/mL G418 or 1 mg/mL
puromycin. Individual antibiotic-resistant colonieswere isolated after
3 weeks of culture, and eventually, two clones with strong Ucma
overexpression or knockdownwere selected. Negative control clones
were randomly selected after transfection with an empty vector and
were designated as the mock control.
Statistical analysis
All data are presented as mean ± standard deviation (SD). Sta-
tistical signiﬁcance of the differences among the groups was
determined using ANOVA or Student's t test. Cell cultureexperiments were performed independently at least three times
and each experiment was performed in duplicate. A P value <0.05
was considered to denote statistical signiﬁcance.Results
Differential gene expression in Runx2-and/or Osx-deﬁcient calvaria
To compare the differential expression of genes during osteo-
genesis under conditions of Runx2 and/or Osx deﬁciency, DNA
microarray analysis was performed using calvarial RNA isolated from
WT, Runx2het, Osxhet, and Doublehet embryos at E18.5 (Fig. S2).
Twenty-six genes that are classiﬁed as regulators of osteogenesis
showed differences in expression, with a fold change of at least 1.5
under conditions of Runx2 and/or Osx deﬁciency (Fig. 1). In compari-
son to the embryos of other genotypes, the expression of Indian
hedgehog, Dentin sialophosphoprotein (Dspp), 30-phosphoadenosine
50-phosphosulfate synthase 2 (Papss2), andUcmawas downregulated
in Doublehet embryos. In particular, compared to the WT, Ucma was
downregulated by 50% in Runx2het andOsxhet embryos, and by 80% in
Doublehet embryos. The expression and function of Dspp and Papss2
have been studied in bone, but few studies have explored the role of
Ucma. Thus, we focused on Ucma in the present study.Ucma expression in osteoblasts
To validate the disrupted Ucma expression detected by
microarray analysis, RT-PCR and qRT-PCR were performed using
calvarial mRNA. Compared to WT, Ucma expression decreased in
the Runx2het and Osxhet animals, and further decreased in the
Doublehet animals [Fig. 2(A)]. Moreover, Ucma expression was
signiﬁcantly reduced in the Osx knockout (KO) and Runx2 KO
animals [Fig. 2(B)]. To minimize the inﬂuence of differences in
residual cartilage of the calvariae, we examined the expression of
cartilage genes. The expression of Col2a1, Sox9, and aggrecan was
identical in the calvarial tissue samples [Fig. S3(A) and (B)].
Furthermore, in rib cage cartilage, Ucma and Col2a1 expressions
was not signiﬁcantly different [Fig. S3(C)]. Expression of Ucma
and Col2a1 in rib cage cartilage was higher than that in the
calvaria, but their expression was detected in calvarial tissue
[Fig. S3(D) and (E)]. To analyze the regulation of Ucma expression
Fig. 1. Genes affected by Runx2 and Osx during osteogenesis. Microarray analysis was performed with pooled RNA isolated from embryos with the same genotype. Expression of 26
osteogenic genes was altered between wild-type (WT), and Runx2het, Osxhet, and Doublehet genotypes. Upregulation or downregulation of genes under conditions of Runx2 and/or
Osx deﬁciency is presented as fold change in gene expression relative to wild-type, which was set as 1.0. Expression of the Ucma gene was signiﬁcantly decreased in Doublehet
embryos compared to Runx2het and Osxhet embryos.
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encoding Runx2, Osx, or both. Ucma expression increased in os-
teoblasts overexpressing either Runx2 or Osx. In addition, Ucma
expression further increased upon overexpression of both Runx2
and Osx [Fig. 2(C)]. These results suggest that Runx2 and Osx
function together to regulate Ucma expression in MC3T3-E1 os-
teoblasts. To examine the change in Ucma expression during
osteoblast differentiation, we cultured MC3T3-E1 cells for 30
days in differentiation medium. Osteoblast differentiation was
conﬁrmed by measuring the expression of differentiation
markers, the patterns of which were identical when measured by
RT-PCR or qRT-PCR (Fig. 3). Runx2 expression was consistently
high at all stages of differentiation. Osx expression was observed
at the beginning of differentiation; it gradually increased
throughout the differentiation process. A late-stage marker of
osteoblast differentiation, osteocalcin, was highly expressed at
the end of the differentiation process. Weak Ucma expression
was detected on day 5 of differentiation, and then was clearly
detected from the mid-stage of differentiation until osteoblast
differentiation was complete.
Transcriptional activity of the mouse Ucma promoter is responsive
to Runx2 and/or Osx
To test whether Runx2 and/or Osx contribute to the transcrip-
tional activity of Ucma, we cloned the mouse Ucma promoter. The
transcription initiation site of the mouse Ucma gene wasdetermined using 50 RACE. The 50 RACE product was puriﬁed and
sequenced to identify the transcription initiation site (Fig. S4).
MC3T3-E1 cells transfected with pUcma-980 and either the Runx2
or the Osx expression vectors exhibited increased luciferase activity
in a dose-dependent manner [Fig. 4(B)]. Transcriptional activity of
the Ucma promoter increased further when both vectors were
transfected into the cells. This result suggested that the effects of
Runx2 and/or Osx on the activation of Ucma transcription were
dose-dependent.
We performed TFSEARCH (Searching Transcription Factor
Binding Sites, version 1.3) analysis of the 1-kb promoter sequence
of Ucma to identify transcription factor binding sites. Osx, a
member of the Sp family, contains a DNA-binding domain that
binds GC-rich sequences and Sp1 elements to control target gene
expression5,11,12. AML elements of target genes are putative Runx2-
binding sites (PuACCPuCA or TGTGGT)16,17. Within the Ucma pro-
moter, two Sp1-binding sites, two GC-rich regions and three
Runx2-binding sites were identiﬁed [Fig. 4(A) and Fig. S4]. There-
fore, the transcriptional activity of Ucma may be regulated by
Runx2 and Osx through these binding sites. To determine which
regions of the Ucma promoter are essential for Runx2-and Osx-
mediated activation, 50-truncated mutants of the Ucma promoter
were generated and examined using a luciferase assay [Fig. 4(C)].
Deletion of the region between positions 222 and 41 signiﬁ-
cantly reduced Runx2-and Osx-induced Ucma promoter activity
[Fig. 4(C)]. This result indicated that the 222/41 region in the
Ucma promoter was responsive to Runx2 and Osx.
Fig. 2. Alteration of Ucma expression by Runx2 and/or Osx gene deﬁciency or overexpression. (A) Reduced expression of Ucma mRNA in Doublehet embryos. Calvarial tissues of the
same genotype in each pregnant female were pooled and RNA was isolated. Three independent RT-PCR assays were performed using RNA collected from each pregnant female; a
representative image of RT-PCR data is shown. Reduced expression of Ucma in Doublehet embryos was conﬁrmed by qRT-PCR. (B) Reduced expression of Ucma in Runx2 KO and Osx
KO embryos by qRT-PCR. The results are presented as mean ± SD. *Mean values were signiﬁcantly different from the wild-type (P < 0.05). (C, D) Ucma induction upon Runx2 and/or
Osx overexpression in MC3T3-E1 osteoblastic cells. MC3T3-E1 cells were transfected with either Runx2 or Osx expression vectors, or both vectors (designated “Double”). Ucma
mRNA expression was strongly increased in the Double samples according to RT-PCR (C) and qRT-PCR (D). The intensity of individual bands after RT-PCR [shown in Fig. 2(C)] was
determined using the Image J software. The data were normalized to Gapdh and calculated as a fold change relative to control pcDNA only, which was set to 1.0. Relative expression
levels shown in Fig. 2(D) were plotted against those of respective genes in control pcDNA only data, which were set to 1.0. The data are presented as mean ± SD of three independent
experiments. *Mean values were signiﬁcantly different from pcDNA only (P < 0.05). #Mean values were signiﬁcantly different from Osx only (P < 0.05). yMean values were
signiﬁcantly different from Runx2 only (P < 0.05).
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Runx2-binding site, one GC-rich region, and one Sp1-binding site.
To determine whether these sites were response elements for
Runx2-and/or Osx-mediated transcriptional activation of Ucma, we
performed site-directed mutagenesis [Fig. 4(D)]. Runx2-and Osx-
mediated activation of the Ucma promoter was strongly attenu-
ated after mutation of the Runx2-binding site and/or the Sp1-
binding site within the 222/41 region [Fig. 4(D)]. However,
mutation of the GC-rich region did not affect Runx2-or Osx-
mediated transcription. These results indicated that the Runx2-
and Sp1-binding sites within the 222/41 region played a
crucial role in Runx2-and Osx-responsive Ucma transcription,respectively. To determine whether Runx2 and Osx bind directly to
their respective binding sites within the 222/41 region, we
performed a ChIP assay. After precipitation of chromosomal DNA by
using an anti-Osx or anti-Runx2 antibody, the promoter region
harboring the Runx2-and Sp1-binding sites was ampliﬁed suc-
cessfully, indicating that Runx2 and Osx directly bound to their
respective response elements within the promoter [Fig. 4(E) and
Fig. S5]. Wewere not able to amplify the GC-rich region of the Ucma
promoter from the precipitated DNA. The potential Runx2 and Osx
binding sites within the Ucma promoter are conserved among
different species including human, rabbit, mouse, rat, guinea pig,
and dog (Fig. S5). In particular, they are completely conserved
Fig. 3. Increased expression of Ucma during osteoblast differentiation. At the indicated time points, expression of Ucma and marker genes was analyzed using RT-PCR (A) and qRT-
PCR (B). After induction of Runx2 and Osx expression, Ucma was clearly induced mid-way through osteoblast differentiation and continued during the course of the differentiation
process. Osteocalcinwas expressed at the late stage of osteoblast differentiation. The intensity of the individual bands in the RT-PCR image shown in Fig. 3(A) was determined using
the Image J software, and the data that were normalized to Gapdh were calculated as a fold change relative to control (differentiation day 0), which was set to 1.0. Relative
expression levels shown in Fig. 3(B) were plotted against those of the respective genes on differentiation day 0, which were set to 1.0. The data are presented as mean ± SD of three
independent experiments.
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directly to the Runx2-and Sp1-binding sites within the 222/41
region of the mouse Ucma promoter, respectively, and activated
Ucma transcription.
Ucma partially increases osteoblast differentiation
To determine whether Runx2-activated and Osx-activated
Ucma expression are required for osteoblast differentiation, we
generated Ucma-overexpressing stable clones. Compared to themock control, in an Ucma-overexpressing stable clone, the mRNA
expression of Ucma was strong throughout the entire period of
cell differentiation. The major marker of late-stage differentiation
in osteoblasts, osteocalcin expression, was elevated at the early
stages of osteoblast differentiation [Fig. 5(A) and (B)]. An identical
pattern was observed in another stable clone [Fig. S6(A)]. The
expression level of the other osteoblast marker gene, osteopontin,
also increased in the Ucma-overexpressing cells [Fig. S6(D) and
(E)]. Alkaline phosphatase (ALP) staining also indicated that dif-
ferentiation was enhanced in Ucma-overexpressing osteoblasts
Fig. 4. Ucma transcriptional activity activated by Runx2 and/or Osx. (A) Putative binding sites of Runx2 and Osx were identiﬁed in the promoter region of Ucma by using the
TFSEARCH software. Within the 1-kb Ucma promoter, two Sp1-binding sites, two GC-rich regions, and three Runx-binding sites were found. (B) MC3T3-E1 cells were co-transfected
with pUcma-luc and vectors expressing the transcription factors, Runx2 and/or Osx, at the concentration of 30 and/or 100 ng, respectively. Ucma transcription was activated by
either Osx or Runx2 in a dose-dependent manner. Transcriptional activity of Ucma was highly increased by the addition of both Runx2 and Osx. (C) Identiﬁcation of the Runx2 and
Osx-responsive regions in the mouse Ucma promoter. The full-length mouse Ucma promoter (pUcma-980) or one of three 50 deletion mutants (pUcma-459, -222, and -41) was
transiently cotransfected with either Runx2 and/or Osx expression vectors or the pcDNA empty vector into MC3T3-E1 cells. Luciferase activity was normalized to that of Renilla
luciferase in each sample. Relative luciferase activity was expressed as fold induction over the Ucma/luciferase reporter activity in the presence of the pcDNA control vector. A
signiﬁcant decrease in Runx2-and Osx-induced Ucma transcriptional activity was observed after deletion of the regions between positions 222 and 41 of the Ucma promoter. The
results are presented as mean ± SD of three independent experiments. *Mean values were signiﬁcantly different from pcDNA only data (P < 0.05). #Mean values were signiﬁcantly
different from Osx only data (P < 0.05). yMean values were signiﬁcantly different from Runx2 only data (P < 0.05). (D) Identiﬁcation of the Runx2-and Osx-responsive regions in the
mouse Ucma promoter using site-directed mutagenesis. Four mutations (-980/mGC, -980/mSp1, -980/mRunx2, and -980/mDouble) within the 222/41 region of the mouse Ucma
promoter were generated as shown in the diagram. Ucma transcriptional activity was signiﬁcantly reduced after mutation of the Runx2-and/or Sp1-binding sites. The results are
presented as mean ± SD of three independent experiments. *Mean values were signiﬁcantly different from pcDNA only data (P < 0.05). #Mean values were signiﬁcantly different
from Osx only data (P < 0.05). yMean values were signiﬁcantly different from Runx2 only data (P < 0.05). (E) Schematic representation of the Runx2-and Sp1-binding sites in the
Ucma promoter indicated by the primer sets used in the ChIP assay. Chromatin from MC3T3-E1 cells that were transfected with Runx2 or Osx expression vector was subjected to
immunoprecipitation with an anti-Osx antibody (a-Osx), anti-Runx2 antibody (a-Runx2), or isotype-matched control antibody (Con). The direct binding of Runx2 and Osx to the
Ucma promoter was determined by PCR.
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started earlier and was more frequent in the Ucma-
overexpressing stable clone than in the mock control [Fig. 5(C)
and Fig. S6(C)]. These results demonstrated that Ucma-
overexpressing osteoblasts differentiated faster than did themock control cells, meaning that osteoblasts were more mature as
a result of increased Ucma expression.
Ucma is secreted after removal of its signal peptide13,14. After
transient transfection of 293FT cells with the Ucma expression
vector, Ucma was detected in the medium as well as in cell lysates
Fig. 5. Ucma-induced osteoblast differentiation. (A) In osteoblasts overexpressing Ucma, Ucma and osteocalcin expression levels were elevated during the entire period of osteoblast
differentiation by RT-PCR. (B) Compared to the mock control, the expression of Ucma and osteocalcin was elevated at the early stages of differentiation as conﬁrmed by qRT-PCR in
Ucma overexpressing osteoblasts. Relative expression levels were plotted against those of respective genes on differentiation day 0 of the mock control, which were set to 1.0. *Mean
values were signiﬁcantly different from the mock control at indicated time points (P < 0.05). (C) Alizarin red-S staining and OD value analysis were used to evaluate the level of
mineralized nodule formation. Mineralized nodule formation started earlier and was more frequent in Ucma-overexpressing osteoblasts compared to the mock control. (D) Ucma
protein was detected in the culture medium and cell lysates of 293FT cells transiently transfected with Ucma. (E) Increased formation of mineralized nodules was observed in
MC3T3-E1 osteoblastic cells grown for 5 days in a medium containing the secreted Ucma protein. The large and thick mineralized nodules stained by alizarin red S were counted in
several visual ﬁelds (more than ﬁve ﬁelds per well) of culture plates. Relative mean ± SD for the number of mineralized nodules are shown underneath the images. Scale
bar ¼ 500 mm *P < 0.05. (F) Increased formation of mineralized nodules was observed in primary osteoblast cells cultured in a medium containing the secreted Ucma protein for 10
days. All cell culture experiments were performed independently in triplicate. A representative result is shown.
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subsequently secreted into the culture supernatant. To determine
whether the secretion of Ucma is important for osteoblast differ-
entiation or nodule formation, we added the cell culture medium
containing Ucma to MC3T3-E1 osteoblasts for 5 days of differenti-
ation. The mineralized nodule formation and osteocalcin expression
were signiﬁcantly increased in cells cultured in medium containing
secreted Ucma, compared to that observed in osteoblasts cultured
in control medium from the pcDNA-transfected cells [Fig. 5(E) and
Fig. S7(A)]. Enhanced mineralization was also evaluated by ALP
staining [Fig. S7(B)]. The ability of secreted Ucma to enhance dif-
ferentiationwas also conﬁrmed in primary osteoblast cells [Fig. 5(F)
and Fig. S7(C)e(E)]. This result suggested that the Ucma stimulated
osteoblast differentiation and nodule formation.
Ucma is necessary for Runx2-or Osx-dependent osteoblast
differentiation
To determine whether the Ucma knockdown has any effect on
Runx2-or Osx-dependent osteoblast differentiation, Ucma shRNA
was generated and Ucma knockdown was tested in 293FT cells co-
transfected with Ucma expression vector by western blotting
[Fig. 6(A)]. Immunoblotting showed that Ucma protein levels were
remarkably decreased in shUcma cells. Then, we silenced Ucmawith the veriﬁed Ucma shRNA in MC3T3-E1 osteoblasts. Osteoblast
differentiationwas signiﬁcantly reduced inMC3T3/shUcma cells, as
observed by osteocalcin expression [Fig. 6(B)]. Nonetheless, nodule
formation and osteocalcin gene expression were partially rescued
in MC3T3/shUcma cells cultured for 10 days in a medium con-
taining secreted Ucma protein [Fig. 6(C) and (D)]. Even though
Runx2 or Osx was overexpressed, the expression of Ucma and
osteocalcinwere not increased in MC3T3/shUcma cells compared to
MC3T3/Mock cells [Fig. 6(E)]. These results indicate that Ucma is
required for Runx2-and Osx-dependent osteoblast differentiation.
Discussion
Runx2 and Osx, master transcription factors of osteogenesis, are
upregulated by BMP signaling during osteogenesis. Runx2 expres-
sion and function are controlled through BMP-activated Smad
signaling, and BMP2 up-regulates Osx expression in osteoblasts.
According to the results from KO mouse models5, Osx is a down-
stream target of Runx2 during osteogenesis. Osx expression, how-
ever, is not upregulated in Runx2-overexpressing osteoblasts, as
shown in Fig. 2(C). Several reports have demonstrated that BMP2-
induced Osx expression is mediated by both Runx2-dependent and
independent pathways in vitro. BMP2-induced Runx2 or Osx
expression is mediated by Dlx518,19. In addition, Osx expression is
Fig. 6. The effect of Ucma knockdown on osteoblast differentiation. (A) Ucma protein levels in mock and shUcma cells were analyzed by western blotting. Immunoblot intensities
for Ucma/b-actin were quantitated by densitometry. Intensities of mock cells were set at 100%. A representative result is shown. (B) Ucma knockdown by shRNA resulted in the
reduction of osteocalcin in MC3T3/shUcma cells. The mRNA expression of Ucma and osteocalcin in MC3T3/mock and MC3T3/shUcma cells were evaluated by qRT-PCR. Relative
expression levels were plotted against those of respective genes on differentiation day 0 of the mock control, which were set to 1.0. (C) Nodule formation increased in MC3T3/
shUcma cells cultured in a medium containing the secreted Ucma protein for 10 days. (D) The expression of osteocalcin was increased in MC3T3/shUcma cells grown in a medium
containing the Ucma protein during differentiation as conﬁrmed by qRT-PCR. Relative expression levels were plotted against those of osteocalcin on differentiation day 0 of MC3T3/
shUcma cells, which were set to 1.0. (E) The mRNA expression of Ucma and osteocalcin did not change in MC3T3/shUcma cells overexpressing Runx2 or Osx compared to MC3T3/
mock cells. Relative expression levels were plotted against those of respective genes in control pcDNA only data of the mock control, which were set to 1.0.
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cells, and is not induced in Runx2-overexpressing C2C12 cells19.
Together, these results suggest that Dlx5 independently regulates
the expression of Runx2 and Osx. Another study also conﬁrmed that
Osx expression is induced by BMP-2 in Runx2-deﬁcient cells, and
this induction is inhibited by an Msx2 knockdown or by the
expression of an inhibitory Smad, suggesting that Osx is regulated
via both Runx2-dependent and Runx2-independent pathways20.
These observations indicate that Osx expressed in bone may not be
regulated by Runx2 exclusively. This may be the reason that Osx
expression is not upregulated by Runx2 overexpression. Runx2 and
Osx, however, are still responsible for the regulation of additional
genes downstream of BMP signaling7e12. Recent studies have
shown that NEL-like 1 (Nell-1) is downstream of both Runx2 and
Osx during osteoblast differentiation21,22. In Runx2 heterozygotes,
aberrant osteoblastic gene expression and calvarial defects are
reversed by Nell-1 overexpression21. Nell-1 transcription is nega-
tively regulated by Osx, indicating that Nell-1, controlled by the
crosstalk between Runx2 and Osx, may perform an important
function in osteoblast differentiation22. Nevertheless, genes thatare targeted by both Runx2 and Osx during the regulation of
osteoblast differentiation and function are still unknown. A better
understanding of the regulation of osteogenesis by Runx2-and Osx-
controlled genes may facilitate the development of new bone
anabolics.
To identify the genes downstream to both Runx2 and Osx that
act as transcriptional regulators during osteogenesis, we conducted
DNA microarray analysis. Among the 26 genes that were differen-
tially expressed during osteogenesis as a result of a Runx2 and/or
Osx deﬁciency, expression of osteocrin and jun proto-oncogene
related gene d (JunD) was upregulated, while expression of Dspp,
Papss2, and Ucma was downregulated in Doublehet embryos.
Osteocrin is a signaling molecule that modulates the osteoblast
phenotype and bone growth23, and Papss2 promotes ALP activity
and mineralization in osteoblasts24. Even though Dspp in bone is
not as highly expressed as that in tooth, regulatory mechanisms
governing DSPP expression are involved in both tissues25. JunD
regulates bone sialoprotein expression, which is detected in human
osteotropic cancers26. The few studies mentioned above showed
that osteocrin, JunD, Dspp, and Papss2 might be closely linked to
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observed in osteoblasts and osteocytes, but its function remains
unclear in osteogenesis. Nonetheless, there have been few studies
on whether Runx2 and/or Osx regulate the expression of Ucma
during osteoblast differentiation and bone formation.
Surmann-Schmitt and colleagues14 reported that Ucma is
expressed at the early stages of osteoblast differentiation and that
the recombinant protein interferes with osteoblast differentiation,
suggesting that Ucma inhibits osteogenic differentiation. However,
Viegas and colleagues15 observed the expression of Ucma in oste-
oblasts and osteocytes, as well as in chondrocytes, and provided
information based on tissue-speciﬁc EST data, arguing for the
cartilage-speciﬁc expression of Ucma. In the present study, Ucma
expression and regulation were observed in osteoblasts. Ucma
expression was monitored during 30 days of differentiation. Ucma
expression was negligible in MC3T3-E1 cells before differentiation,
but began on day 5 and increased continuously throughout the
differentiation period. At the early stage of osteoblast differentia-
tion, Ucma expression is quite low in spite of the upregulation of
Runx2 and Osx. This ﬁnding indicates that neither Runx2 nor Osx
alone is sufﬁcient, and that either higher levels of Runx2 and Osx
expression, or other factors, are needed to increase Ucma expres-
sion. Doublehet embryos have a reduced area of mineralized bones
and delayed bone formation compared to Runx2het and Osxhet
embryos6. This result also supports the ﬁndings that low levels of
Runx2 and Osx expression reduced the transcriptional activity of
Ucma, ﬁnally resulting in the reduction of osteoblast differentiation
and mineralization. Nevertheless, Ucma expression in osteoblasts
can be a controversial issue. Col2 is believed to be a chondrocyte-
speciﬁc marker. Even though quite low when compared to
expression in rib cartilage, Col2a1 expression was still observed in
calvaria, as shown in Fig. S3. This result suggests either that cal-
variae are contaminated with cartilage with chondrocytes or that
some osteoblastic cell populations in calvariae are derived from
chondrocytes.
Ucma has a conserved cleavage site for subtilisin-like proprotein
convertases (SPCs). Among SPC family members, SPC4 and PC6A
are attached to heparin sulfate proteoglycans, which are abundant
in cartilage matrix, indicating that they are responsible for the
cleavage of Ucma in cartilage27. Several SPCs also are expressed in
cartilage including furin, SPC6, and SPC728,29. Surmann-Schmitt
and colleagues14 generated and used Ucma-C protein (C-terminal
fragment of Ucma) that is proteolytically processed by a furin-like
protease and found in the entire cartilage matrix. However, it was
not studiedwell for the SPCs abundant in osteoblasts or bone. In the
present study, full-length Ucma (approximately 20 kD) was detec-
ted in cell lysates and the cleaved form of the signal peptide of
Ucma (approximately 16 kD) was detected in cell medium. How-
ever, the smallest cleavage form of Ucma (approximately 12 kD),
resulting from processing by convertases, was not observed during
or after secretion. This suggests that SPCs for Ucma processing are
cell type dependent or that uncleaved Ucma plays a different role
from Ucma-C, which is processed in chondrocytes. An interesting
study showed that Ucma is required for skeletal development in
zebraﬁsh; speciﬁcally, an Ucma knockdown results in severe
growth retardation and impaired skeletal development30. Secreted
Ucma proteins accumulate in soft tissue, including the skin and
vascular system, to affect calciﬁcations, indicating that Ucma plays
a role in mineral formation31. A recent report showed that the
sequence variants found in the Ucma basal promoter are associated
with Paget's disease of the bone32. Together, these ﬁndings suggest
that Ucma regulates osteoblast differentiation and mineralization.
In the present study, formation of mineralized nodules during
differentiation is markedly enhanced in Ucma-overexpressing os-
teoblasts and in cells cultured in a medium containing the secretedUcma protein. Moreover, in Ucma-overexpressing osteoblasts, the
expression of osteocalcin seems to be upregulated. Even though it is
not clear whether Ucma directly increases osteocalcin expression, it
is obvious that Ucma-overexpressing osteoblasts are more mature
than mock control cells. As a result of increased Ucma expression,
osteoblasts differentiate faster than do mock control cells; this
ﬁnding was conﬁrmed by the increased expression of osteocalcin,
which is a major marker of late-stage differentiation in osteoblasts.
Increased expression of osteopontin also proved that Ucma-
overexpressing osteoblasts are more mature than mock control
cells. On comparing Ucma and osteocalcin expression during
osteoblast differentiation, the expression patterns of Ucma and
osteocalcin were found to be similar; however, additional experi-
mental evidence must be gathered to conclude that Ucma is a late
stage marker for osteoblast differentiation.
Eitzinger and colleagues33 reported that skeletal development is
normal in Ucma-deﬁcient mice and that Ucma is not necessary for
endochondral ossiﬁcation during development. Although Ucma
does not have a decisive function in skeletal development, our re-
sults demonstrate that increased Ucma expression promote osteo-
blast differentiation, thereby resulting in enhanced bone formation.
Further reﬁnement of mouse models of osteoblast-speciﬁc Ucma-
overexpression should help researchers understand the in vivo
function of Ucma in the promotion of bone formation. Conse-
quently, our results suggest that Ucma may be involved in ho-
meostasis and enhancement of the skeleton under certain
pathological conditions, such as aging, disease, or fractures.
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